Management of non-complicated BPH: Proposition of a renewed decision tree

World Journal of Urology

Volumn 24, Issue 4, 2006, Pages 367-370

  Desgrandchamps, Francois ^a   de la Taille, Alexandre ^b   Azzouzi, Abdel Rahmène ^c   Fourmarier, Marc ^d   Haillot, Olivier ^e   Lukacs, Bertrand ^f   Saussine, Christian ^g  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY HOSPITAL OF TOURS   (France)

^f HÔPITAL TENON   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DECISION TREE; HUMAN; HYPERTHERMIC THERAPY; MALE; PROSTATE HYPERTROPHY;

DECISION TREES; HUMANS; HYPERTHERMIA, INDUCED; MALE; PROSTATIC HYPERPLASIA;

EID: 33748099358     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0096-9     Document Type: Article

References (21)

1. Arrighi HM, Metter EJ, Guess HA, Fozzard JL (1991) Natural history of benign prostatic hyperplasia and risk of prostatectomy: The Baltimore longitudinal study of aging. Urology 38(1):4-8
2. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, Lieber MM (1993) The prevalence of prostatism: A population-based survey of urinary symptoms. J Urol 150(1):85-89
3. Guess HA, Chute CG, Garraway WM, Girman CJ, Panser LA, Lee RJ, Jacobsen SJ, McKelvie GB, Oesterling JE, Lieber MM (1993) Natural history of prostatism - urinary flow rates in a community-based study. J Urol 150(3):887-892
4. Piercy GB, Deber R, Trachtenberg J, Ramsey EW, Norman RW, Goldenberg SL, Nickel JC, Elhilali M, Perrault JP, Kraetschmer N, Sharpe N (1999) Impact of a shared decision-making program on patients with benign prostatic hyperplasia. Urology 53(5):913-920
5. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA (2003) Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. For the MTOPS research Group. The long term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2385-2396
6. Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H (2005) Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): A systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 8(3):206-209
7. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, Tubaro A, Nickel JC (2003) Benign prostatic hyperplasia: A progressive disease of aging men. Urology 61(2):267-273
8. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J (1999) Serum prostate specific antigen and prostate volume predict long term changes in symptoms and flow rate: Results of a four year randomized trial comparing finasteride versus placebo. Urology 54(4):662-669
9. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002, ARIA3003 Study Investigators (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434-441
10. Fitzpatrick JM, Desgrandchamps F (2005) The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia. BJU Int 95(4):575-579
11. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP (2002) Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: A 1-year randomized international study. Eur Urol 41(5):497-506
12. Kirby RS (2003) A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 91(1):41-44
13. Verhamme KM, Dieleman JP, Bleumink GS, Bosch JL, Stricker BH, Sturkenboom MC (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: The triumph project. Eur Urol 44:539-545
14. Desgrandchamps F, Mongiat-Artus P (2006) Dosage and duration of medication for men with lower urinary tract symptoms: Two questions without definitive answers. Curr Opin Urol 16(1):37-39
15. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB (2003) Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol 44:461-466
16. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB (2004) Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94(6):817-820
17. Desgrandchamps F (2004) Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: A reflection from MTOPS. Curr Opin Urol 14(1):17-20
18. Zlotta AR, Giannakopoulos X, Maehlum O, Ostrem T, Schulman CC (2003) Long-term evaluation of transurethral needle ablation of the prostate (TUNA) for treatment of symptomatic benign prostatic hyperplasia: clinical outcome up to five years from three centers. Eur Urol 44:89-93
19. Tan AH, Nott L, Hardie WR, Chin JL, Denstedt JD, Razvi H (2005) Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 19(10):1191-1195
20. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ (2004) EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 46(5):547-554
21. AUA practice guidelines committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170:530-547